Items where Author is "Wyss, P. A."

1996

Schürch, F. and Meier, P. J. and Wyss, P. A.. (1996) Akute Intoxikationen mit Thioridazin = acute poisoning with thioridazine. Deutsche medizinische Wochenschrift, Jg. 121, H. 33. pp. 1003-1008.

Mühlebach, S. and Steger, P. and Conen, D. and Wyss, P. A.. (1996) Erfolgreiche Therapie akuter Salizylatintoxikationen mit Glycin und Aktivkohle. Schweizerische Medizinische Wochenschrift, 126 (49). pp. 2127-2129.

1995

Krähenbühl, S. and Sauter, B. and Kupferschmidt, H. and Krause, M. and Wyss, P. A. and Meier, P. J.. (1995) Case report : reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. American journal of the medical sciences, Vol. 309, H. 6. pp. 315-316.

1991

Mühlebach, S. and Moor, M. J. and Wyss, P. A. and Bickel, M. H.. (1991) Kinetics of distribution and elimination of DDE in rats. Xenobiotica, 21 (1). pp. 111-120.

Mühlebach, S. and Wyss, P. A. and Bickel, M. H.. (1991) The use of 2,4,5,2',4',5'-hexachlorobiphenyl (6-CB) as an unmetabolizable lipophilic model compound. Pharmacology and Toxicology, 69 (6). pp. 410-415.

1986

Wyss, P. A. and Mühlebach, S. and Bickel, M. H.. (1986) Long-term pharmacokinetics of 2,2',4,4',5,5'-hexachlorobiphenyl (6-CB) in rats with constant adipose tissue mass. Drug Metabolism and Disposition, 14 (3). pp. 361-365.

1985

Mühlebach, S. and Wyss, P. A. and Bickel, M. H.. (1985) Comparative adipose tissue kinetics of thiopental, DDE and 2,4,5,2',4',5'-hexachlorobiphenyl in the rat. Xenobiotica, 15 (6). pp. 485-491.

1983

Jondorf, W. R. and Wyss, P. A. and Mühlebach, S. and Bickel, M. H.. (1983) Disposition of 2,2',4,4',5,5'-hexachlorobiphenyl (6-CB) in rats with decreasing adipose tissue mass. II. Effects of restricting food intake before and after 6-CB administration. Drug Metabolism and Disposition, 11 (6). pp. 597-601.

1982

Wyss, P. A. and Mühlebach, S. and Bickel, M. H.. (1982) Pharmacokinetics of 2,2',4,4',5,5'-hexachlorobiphenyl (6-CB) in rats with decreasing adipose tissue mass. I. Effects of restricting food intake two weeks after administration of 6-CB. Drug Metabolism and Disposition, 10 (6). pp. 657-661.